Media

Anesiva Elects James N. Campbell to Board of Directors

SOUTH SAN FRANCISCO, Calif., June 29, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that James N. Campbell, M.D., director of the Blaustein Pain Treatment Center at Johns Hopkins University School of Medicine, has been elected to its board of directors. Dr. Campbell, a former president of the American Pain Society, was one of the doctors involved in the earliest research of Adlea(TM) (formerly 4975).

"Dr. Campbell has been on the forefront of pain management for over 25 years and shares our drive to get effective, safer solutions for pain on the market and available to physicians and patients," said John P. McLaughlin, chief executive officer of Anesiva. "We are pleased to have Jim join our board at this critical time as we prepare to market Zingo(TM), our lead product candidate for the reduction of pain associated with venipunctures, and advance Adlea into late-stage trials in various indications."

James Campbell, M.D. is professor of Neurosurgery in the Department of Neurosurgery at the Johns Hopkins University School of Medicine and director of the Blaustein Pain Treatment Center. He is also founder, president, and chairman of the board of the American Pain Foundation. He received the Jacob Javits Neuroscience Investigator Award from the National Institutes of Health in 1988. Also in 1988, he received the Frederick W.L. Kerr Award from the American Pain Society. In 1992 he received an unrestricted award for outstanding research in pain from the Bristol-Myers Squibb Corporation. He also received the Grass Award from the Society of Neurological Surgeons. Dr. Campbell is a past president of the American Pain Society, has authored over 100 peer-reviewed studies and has contributed to several textbooks as well, in addition to being lead editor of three books. Dr. Campbell earned his BA in Psychology from the University of Michigan and his M.D. from Yale University, School of Medicine.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has two drug candidates in development for multiple pain-related indications. A New Drug Application (NDA) has been filed for the most advanced product, Zingo. The second product in the pipeline, Adlea (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could,"

"should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: whether Anesiva can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's Form 10-K for the year ended December 31, 2006.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

SOURCE Anesiva, Inc.

Jennifer Cook Williams, Vice President, Investor Relations of Anesiva, Inc.,
+1-650-624-9600, [email protected]

http://www.anesiva.com

News Provided by COMTEX